Compare Quest Diagnostics Inc (DGX) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Tidewater Inc — how do they compare? Quest Diagnostics Inc trades at $204.84 (market cap $22.80B), while Tidewater Inc trades at $73.19 (market cap $3.68B). The key difference: Quest Diagnostics Inc is far larger — about 6.2× Tidewater Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.
| DGX | TDW | |
|---|---|---|
Market Cap | $22.80B | $3.68B |
Sector | Health | Utilities |
52-Week High | $216.02 | $91.12 |
52-Week Low | $166.42 | $46.32 |
Enterprise Value | $28.82B | $3.78B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Tidewater (TDW) trades at $74.35, up 1.34% today, with a bullish technical outlook driven by moving averages and ADX signals. Recent earnings show volatility with Q1 2026 missing estimates at $0.12 versus $0.75 expected, though Q3 2025 beat expectations. The company maintains strong profitability with a 22.16% net margin and robust cash flow from operations of $379.11M in 2025. News highlights include FTAI Infrastructure's acquisition of Tidewater Logistics in June 2026, potentially impacting operations.
The stock presents a mixed outlook; valuation metrics like a P/E of 12.47 suggest potential undervaluation, but earnings misses and a 'Hold' analyst consensus (61.54% hold ratings) indicate caution. Key risks include execution challenges in offshore support services and oil market volatility. Upside hinges on reversing recent earnings underperformance and capitalizing on industry acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
